The use of moisture sorption technique in quantification of the degree of
disorder in micronized salbutamol sulphate

Mykhaylova V., Gorny M., Jakobs M., Urbanetz N.A
Institute of Pharmaceutics and Biopharmaceutics,
Heinrich-Heine-University, Universitaetsstraße 1, 40225 Duesseldorf, Germany
Dry powder formulations used for pulmonary application are preferably prepared using crystalline
powders, because the crystalline state is thermodynamically stable. To ensure that the drug will be
presented to the lower respiratory tract, especially the alveolar region, the aerodynamic diameter of the
particles has to be between 0.5 and 5µm. That is why the drug has to be micronized. During the
milling process the crystalline structure may be destroyed. Generated amorphous areas are mainly
located at the surface of the particles. As a consequence bioavailability, physical stability and
hygroscopicity of such partly amorphous particles may be affected, since during the storage
transformation to the thermodynamically stable crystalline state may take place. Therefore it is not
only important to determine the amorphous content but also to quantify the amount of amorphous
areas in micronized drug.
The amount of the amorphous material can be quantified using techniques like X-ray diffraction,
differential scanning and isothermal calorimetry. The quantification limit of these methods varies
between 10% and 1% depending on the chosen method. It has been reported that the quantification
limit can be reduced down to 0,125% by using moisture sorption. The aim of this study is to determine
whether moisture sorption can be used for the quantification of the amorphous amount in micronized
salbutamol sulphate [1].
Eleven different blends containing 0% to 100% amorphous salbutamol sulphate were produced using
the Turbula shaker mixer (Willy A. Bachofen AG Maschinenfabrik, Switzerland). Amorphous powder
was prepared by spray-drying an aqueous salbutamol sulphate solution in a mini spray dryer B-191
(Büchi Labortechnik GmbH, Switzerland). Micronization of crystalline salbutamol sulphate was
performed in an air jet mill (50AS, Hosokawa Alpine AG, Germany).
Samples, approximately 2 g quantities were examined by the moisture sorption system SPS11 (Project
Messtechnik, Germany). The most important part of this system is the humidity and temperature
controlled chamber as well as a quite precise and sensitive balance. The balance measures weight
changes of the samples exposed to a defined humidity program. The amorphous state possesses a
higher potential to absorb moisture than crystalline materials. That leads to higher water uptake at a
defined relative humidity in comparison to the crystalline material. Due to the instability of the
amorphous state the powder tends to recrystallisation during the raising of the relative humidity. This
can be explained by the fact that the absorbed water acts as a plasticizer. The recrystallization is
accompanied by a loss of water and associated with a mass decrease. The increase and decrease of
mass can be gravimetrically detected and may be used to quantify the amount of amorphous material
in the sample.
At the beginning of the measurements the relative humidity (RH) was set to 0%. In steps of 10% the
relative humidity was raised to 90% and finally to 95%. Subsequently the RH was decreased to 0% the
same way. This cycle was repeated once more. The temperature was set to 25°C and the samples were
weighed in time intervals of 6 minutes.
The correlation between the weight change and the percent of amorphous amount in the samples was
determined. Different methods to generate a calibration curve were tested and the most suitable for the
quantification of the amorphous amount in micronized salbutamol sulphate has been isolated.
[1] Gorny M., Jakobs M., Mykhaylova V., Urbanetz N.A.; Quantifying the degree of disorder in
micronized salbutamol sulphate using moisture sorption analysis, submit ed


Asthma care in the emergency department

Approved 11/08 Division of Pediatric Emergency Medicine Asthma Care in the Emergency Department Clinical Practice Guideline Inclusion: 1) Children 2 years of age or older with a prior history of wheezing, and 2) Children less than 2 years of age with likely Asthma rather than Acute Bronchiolitis Exclusion: History of unstable heart disease or suspicion of other reason for wheezin

Bryssel den 12.9.2012 COM(2012) 512 final EUROPAPARLAMENTETS OCH RÅDETS FÖRORDNING om ändring av förordning (EU) nr 1093/2010 om inrättande av en europeisk tillsynsmyndighet (Europeiska bankmyndigheten), när det gäller dess samspel med rådets förordning (EU) nr …/… om tilldelning av särskilda uppgifter till Europeiska centralbanken i fråga om politiken för tillsyn

Copyright © 2010 Find Medical Article